Vascular effects of prostacyclin: does activation of PPARδ play a role?

Prostacyclin (PGI2 ) is a potent vasodilator that exerts multiple vasoprotective effects in the cardiovascular system. The effects of PGI2 are mediated by activation of the cell membrane G-protein-coupled PGI2 receptor (IP receptor). More recently, however, it has been suggested that PGI2 might also...

Full description

Saved in:
Bibliographic Details
Published inTrends in pharmacological sciences (Regular ed.) Vol. 33; no. 10; pp. 559 - 564
Main Authors Katusic, Zvonimir S, Santhanam, Anantha V, He, Tongrong
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.10.2012
Subjects
Advanced Basic Science
Angiogenesis Modulating Agents - pharmacology
Animals
Cardiovascular System - drug effects
Cardiovascular System - metabolism
Epoprostenol - analogs & derivatives
Epoprostenol - pharmacology
Humans
PPAR delta - agonists
PPAR delta - metabolism
Vasodilator Agents - pharmacology
Online AccessGet full text

Cover

More Information
Summary:Prostacyclin (PGI2 ) is a potent vasodilator that exerts multiple vasoprotective effects in the cardiovascular system. The effects of PGI2 are mediated by activation of the cell membrane G-protein-coupled PGI2 receptor (IP receptor). More recently, however, it has been suggested that PGI2 might also serve as an endogenous ligand and activator of nuclear peroxisome proliferator-activated receptorδ (PPARδ). Consistent with this concept, studies designed to define pharmacological properties of stable PGI2 analogs revealed that beneficial effects of these compounds appear to be mediated, in part, by activation of PPARδ. This review discusses emerging evidence regarding the contribution of PPARδ activation to vasoprotective and regenerative functions of PGI2 and stable analogs of PGI2.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0165-6147
1873-3735
DOI:10.1016/j.tips.2012.05.005